Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
<p>Therapeutic coinhibition of Wnt and PI3K signaling reduces tumor growth in ICC. <b>A,</b> RNA-seq data of human ICC demonstrating a positive correlation between the activity of canonical Wnt signaling and Akt signaling. <b>B,</b> Schematic representation of the KPPTo...
Na minha lista:
| Autor principal: | Nicholas T. Younger (14956251) (author) |
|---|---|
| Outros Autores: | Mollie L. Wilson (14956254) (author), Anabel Martinez Lyons (14956257) (author), Edward J. Jarman (9773166) (author), Alison M. Meynert (14956260) (author), Graeme R. Grimes (14160170) (author), Konstantinos Gournopanos (14956263) (author), Scott H. Waddell (14956266) (author), Peter A. Tennant (14956269) (author), David H. Wilson (14956272) (author), Rachel V. Guest (14956275) (author), Stephen J. Wigmore (14915943) (author), Juan Carlos Acosta (14956278) (author), Timothy J. Kendall (14956281) (author), Martin S. Taylor (14956284) (author), Duncan Sproul (13971883) (author), Pleasantine Mill (256953) (author), Luke Boulter (14956287) (author) |
| Publicado em: |
2025
|
| Assuntos: | |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Registros relacionados
-
Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
por: Nicholas T. Younger (14956251)
Publicado em: (2025) -
Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
por: Nicholas T. Younger (14956251)
Publicado em: (2025) -
Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
por: Nicholas T. Younger (14956251)
Publicado em: (2025) -
Supplementary Table S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
por: Queralt Serra-Camprubí (15050174)
Publicado em: (2025) -
Supplementary Table S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
por: Queralt Serra-Camprubí (15050174)
Publicado em: (2025)